explore -WSS

explore

author：fashion 2025-10-03 00:03:55 - browse：8918

Eric Lander White House science office — Eric Lander resigned as President Biden’s science adviser, after a White House investigation found “credible evidence” that he had violated workplace conduct rules. Photo illustration: Alex Hogan/STAT; Source: Getty

WASHINGTON — An early sign that trouble was afoot in the White House science office came last November, when roughly a dozen of Eric Lander’s staff formed a “culture committee” aimed at improving morale.

The group’s first action, five aides told STAT, was to create a “word cloud” depicting the adjectives they most often used to describe the work environment at the White House Office of Science and Technology Policy. Of the dozens of words submitted, three in particular stood out: “hostile,” “siloed,” and “aggressive.”

Three months later, Lander resigned as President Biden’s science adviser, after Politico reported a White House investigation that found “credible evidence” that he had violated workplace conduct rules.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： The high cost of giving birth even with insurance
Next article： Readout Newsletter: Acadia, Eli Lilly, Madrigal Pharma updates

focus

WSS

How to bring more disabled researchers into academia

Guardant Health colon cancer test endorsed by FDA advisory panel

First medicine developed to treat MASH expected to be approved soon

Novo Nordisk obesity pill bests Wegovy in early trial

CDC marks new Covid

RSV shot was 90% effective at preventing hospitalizations in kids

entertainment

explore

focus

Jerome Adams on the need for new antivirals for Covid

Protect nursing home residents from future pandemics

Affirmative action in medical school literally saved lives

U.S. death rates show how politics are affecting public health

Activists slam private health insurers over coverage restrictions

Readout Newsletter: Acadia, Eli Lilly, Madrigal Pharma updates

How one medical school became remarkably diverse

UnitedHealth quietly bought dozens of outpatient centers

The cancer drug shortage isn’t new — and neither are the solutions

Change Healthcare payments predicted restored March 15

focus

Duchenne drug from Nippon Shinyaku fails in rare confirmatory trial

Novo Nordisk obesity pill bests Wegovy in early trial

New research sheds light on how often breast cancer is overdiagnosed

Amylyx ALS drug failure raises questions and concerns

New research sheds light on how often breast cancer is overdiagnosed

Hospitals need to get ahead of regulations on climate change

hotspot

knowledge

focus

entertainment